BJERKHOLT ERIC — SEC insider filings
SEC reporting owner CIK 1197350. 61 insider filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers the 50 most recent of 61 filings on record, filed 2022-02-14 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 15 legs across 10 filings — 41,255 shares, $447,766 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 20 legs across 15 filings — 104,150 shares, $4,610,719 total (shares × price as filed on priced legs).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 69.
- Largest priced transaction: sale of 9,943 shares @ $98.37 ($978,093) in Mirum Pharmaceuticals, Inc., filed 2026-09-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | CHIEF FINANCIAL OFFICER | 19 | 3 legs · 14,000 sh · $397,692 | 14 legs · 53,283 sh · $4,290,125 | 29 |
| CHINOOK THERAPEUTICS, INC. (KDNY) | Chief Financial Officer | 5 | — | 4 legs · 10,413 sh · $231,714 | 20 |
| CERUS CORP (CERS) | Director | 10 | 3 legs · 25,000 sh · $43,351 | 2 legs · 40,454 sh · $88,880 | 6 |
| CalciMedica, Inc. (CALC) | Director | 9 | 9 legs · 2,255 sh · $6,723 | — | 7 |
| Surrozen, Inc./DE (SRZN) | Director | 4 | — | — | 4 |
| Metagenomi Therapeutics, Inc. (MGX) | Director | 3 | — | — | 3 |
Insider filings — BJERKHOLT ERIC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 18,333 · Sale (S): 9,943 @ $98.37 · Option exercise (M): 18,333 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Sale (S): 6,001 @ $99.90 | EDGAR |
| 2026-07-08 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Sale (S): 3,124 @ $121.67 · Sale (S): 1,048 @ $122.43 · Sale (S): 528 @ $123.84 · Sale (S): 300 @ $124.94 | EDGAR |
| 2026-06-11 | 4 | CERUS CORP (CERS) | Sale (S): 20,454 @ $2.60 | EDGAR |
| 2026-06-11 | 4 | Metagenomi Therapeutics, Inc. (MGX) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Sale (S): 2,258 @ $92.84 · Sale (S): 1,175 @ $93.95 · Sale (S): 1,567 @ $95.12 · Option exercise (M): 2,393 @ $26.49 · Option exercise (M): 2,393 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | CERUS CORP (CERS) | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2026-05-14 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 5,550 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 13,334 · Sale (S): 7,287 @ $91.98 · Option exercise (M): 13,334 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 18,140 (derivative) @ $0 · Grant/award (A): 11,760 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 2,667 · Sale (S): 1,053 @ $96.19 · Option exercise (M): 2,667 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 3,334 · Sale (S): 1,421 @ $93.33 · Option exercise (M): 3,334 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 18,333 · Sale (S): 9,578 @ $76.01 · Option exercise (M): 18,333 (derivative) @ $0 | EDGAR |
| 2025-08-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Sale (S): 8,000 · Option exercise (M): 2,954 @ $26.49 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Metagenomi, Inc. (MGX) | Grant/award (A): 8,572 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | CERUS CORP (CERS) | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2025-05-15 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 1,333 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Metagenomi, Inc. (MGX) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 2,667 · Option exercise (M): 2,667 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-12-16 | 4 | CERUS CORP (CERS) | Sale (S): 20,000 @ $1.78 | EDGAR |
| 2024-11-14 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 475 @ $21.05 | EDGAR |
| 2024-09-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 18,334 · Option exercise (M): 18,334 (derivative) @ $0 | EDGAR |
| 2024-08-28 | 4 | CalciMedica, Inc. (CALC) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | CERUS CORP (CERS) | Grant/award (A): 40,000 @ $5 | EDGAR |
| 2024-06-06 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 1,333 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 470 @ $21.05 | EDGAR |
| 2024-04-22 | 4 | CalciMedica, Inc. (CALC) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Purchase (P): 2,000 @ $24.80 | EDGAR |
| 2024-03-18 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Purchase (P): 2,000 @ $25.80 | EDGAR |
| 2024-01-25 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 32,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2023-12-13 | 4 | CERUS CORP (CERS) | Purchase (P): 10,000 @ $1.62 | EDGAR |
| 2023-09-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Purchase (P): 10,000 @ $29.65 · Grant/award (A): 110,000 (derivative) @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-08-23 | 4 | CERUS CORP (CERS) | Purchase (P): 10,000 @ $1.72 | EDGAR |
| 2023-08-11 | 4 | CHINOOK THERAPEUTICS, INC. (KDNY) | Disposition to issuer (D): 39,371 · Disposition to issuer (D): 144,787 (derivative) @ $26.02 · Disposition to issuer (D): 21,501 (derivative) @ $24.86 · Disposition to issuer (D): 88,000 (derivative) @ $27.10 · Disposition to issuer (D): 84,000 (derivative) @ $14.73 · Disposition to issuer (D): 16,415 (derivative) · +4 more | EDGAR |
| 2023-06-28 | 4 | CalciMedica, Inc. (CALC) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | CERUS CORP (CERS) | Grant/award (A): 40,000 @ $5 | EDGAR |
| 2023-06-01 | 4 | CalciMedica, Inc. (CALC) | Purchase (P): 5 @ $3.25 · Purchase (P): 100 @ $4.09 · Purchase (P): 150 @ $4.20 | EDGAR |
| 2023-05-24 | 4 | CalciMedica, Inc. (CALC) | Purchase (P): 500 @ $3.27 | EDGAR |
| 2023-05-23 | 4 | CERUS CORP (CERS) | Purchase (P): 5,000 @ $2 | EDGAR |
| 2023-05-22 | 4 | CalciMedica, Inc. (CALC) | Purchase (P): 1 @ $2.65 · Purchase (P): 199 @ $2.65 | EDGAR |
| 2023-05-19 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-05-18 | 4 | CalciMedica, Inc. (CALC) | Purchase (P): 800 @ $2.70 · Purchase (P): 200 @ $2.67 · Purchase (P): 300 @ $2.70 | EDGAR |
| 2023-03-27 | 4 | CalciMedica, Inc. (GRAY) | Disposition to issuer (D): 1,429 · Disposition to issuer (D): 1,429 (derivative) | EDGAR |
| 2023-02-15 | 4 | CHINOOK THERAPEUTICS, INC. (KDNY) | Option exercise (M): 2,435 · Sale (S): 857 @ $23.75 · Option exercise (M): 2,435 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | CHINOOK THERAPEUTICS, INC. (KDNY) | Option exercise (M): 7,333 · Sale (S): 2,891 @ $24.68 · Option exercise (M): 7,333 (derivative) @ $0 · Grant/award (A): 84,000 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2022-12-02 | 4 | CHINOOK THERAPEUTICS, INC. (KDNY) | Option exercise (M): 16,414 · Sale (S): 5,770 @ $22.29 · Option exercise (M): 16,414 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | CERUS CORP (CERS) | Grant/award (A): 20,454 @ $0 · Grant/award (A): 39,866 (derivative) | EDGAR |
| 2022-06-03 | 4 | GRAYBUG VISION, INC. (GRAY) | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | CHINOOK THERAPEUTICS, INC. (KDNY) | Option exercise (M): 2,434 · Sale (S): 895 @ $12.74 · Option exercise (M): 2,434 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1197350 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs